Loading...

ELDN ELEDON PHARMACEUTICALS INC US FDA Inspections 8-K Filing

LDN

LDN

ELEDON PHARMACEUTICALS INC

(ELDN)

2025 8-K

Financial Announcement

Stock Exchange Agreement

Quarterly Financial Report

Stock Offering Announced

Financial Update

Financial Restatement Notice

Clinical Trials

Financial Statements

Financial Results

CEO Agreement Update

Financial Results

Trial Data Release

Stock Sale Agreement

Financial Restatement

Accounting Firm Change

Annual Meeting and Incentiv...

Financial Results Announcement

Private Placement

Financial Results Announcement

Financial Results Announcement

Phase 1b Trial Data Announc...

Appointment of Director

Indemnification Agreement A...

Appointment of Director

Financial Results Announcement

Annual Meeting and Incentiv...

Financial Results Announcement

Private Placement

Financial Results Announcement

Press Release and Investor ...

External Links:

Eledon Pharmaceuticals announced updated data from a Phase 1b trial of tegoprubart for kidney transplant patients on August 6, 2025, presented at the World Transplant Congress in San Francisco, and will host a conference call to discuss this data.

AI Assistant

ELEDON PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.